Extracellular vesicles in hepatocellular carcinoma: unraveling immunological mechanisms for enhanced diagnosis and overcoming drug resistance DOI Creative Commons

Lanqian Su,

Yu‐Xin Yue,

Yalan Yan

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 28, 2024

Current research is focused on utilizing EVs as a biopsy tool to improve the diagnostic accuracy of HCC, reduce surgical risk, and explore their potential in modulating drug resistance advancing immunotherapeutic strategies. Extracellular vesicles (EVs) have been increasingly recognized important non-invasive biomarkers hepatocellular carcinoma (HCC) due presence variety biomolecules within them, such proteins RNAs, etc. play key role early detection, diagnosis, treatment, prognostic monitoring HCC. These influence development HCC therapeutic response ways, including influencing tumor microenvironment, resistance, participating immune regulatory mechanisms. In addition, specific molecules miRNAs are regarded markers for treatment recurrence which certain space prospects. this paper, we summarize aspects markers, also discuss questions that may be faced markers.

Language: Английский

Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer DOI Creative Commons
Xin Wei,

Weihua Cao,

Shiyu Wang

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 2623 - 2643

Published: March 1, 2025

In recent years, nanobiotechnology, widely used in hepatoma, holds great promise for improving targeted hepatocarcinoma therapy. On account of the unique properties low toxicity, good tolerance, biocompatibility, and biodegradability new nanomaterials, a drug delivery system (TDDS) has been constructed, which can boost therapeutic effect hepatoma-targeted drugs, reduce minimize off target reactions by enhancing permeability retention (EPR) active targeting, thus existing liver cancer therapy strategies. Different nanoparticles have their own advantages disadvantages. They be loaded with multiple drugs on same nanoparticle also surface modified each other to achieve synergistic anti-tumor effects. This essay provides comprehensive overview current status hepatocarcinoma, nanoparticles' structure, disadvantages nanoparticle, application progress cancer. We hope provide basis future clinical hepatoma using nanotechnology.

Language: Английский

Citations

0
The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment DOI
Jiayun Jiang, Hui Zhang,

Yanjiao Ou

et al.

Immunology Letters, Journal Year: 2025, Volume and Issue: unknown, P. 107003 - 107003

Published: April 1, 2025

Language: Английский

Citations

0
MiR-133a-5p Facilitates Cuproptosis in Hepatocellular Carcinoma Through Targeting of ATP7B DOI Creative Commons
Qiaohui Ren, Xinyue Zhu, Nannan Wang

et al.

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 6607 - 6622

Published: May 1, 2025

Language: Английский

Citations

0
Exploring the modulation of TLR4 and its associated ncRNAs in cancer immunopathogenesis, with an emphasis on the therapeutic implications and mechanisms underlying drug resistance DOI
Mohammad Y. Alshahrani, Enwa Felix Oghenemaro, Jasur Rizaev

et al.

Human Immunology, Journal Year: 2024, Volume and Issue: 86(1), P. 111188 - 111188

Published: Dec. 3, 2024

Language: Английский

Citations

2
GALNT6 drives lenvatinib resistance in hepatocellular carcinoma through autophagy and cancer-associated fibroblast activation DOI

Peihong Zhang,

Shiping Chen,

Jia-Liang Cai

et al.

Cellular Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 24, 2024

Language: Английский

Citations

1
Extracellular vesicles in hepatocellular carcinoma: unraveling immunological mechanisms for enhanced diagnosis and overcoming drug resistance DOI Creative Commons

Lanqian Su,

Yu‐Xin Yue,

Yalan Yan

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 28, 2024

Current research is focused on utilizing EVs as a biopsy tool to improve the diagnostic accuracy of HCC, reduce surgical risk, and explore their potential in modulating drug resistance advancing immunotherapeutic strategies. Extracellular vesicles (EVs) have been increasingly recognized important non-invasive biomarkers hepatocellular carcinoma (HCC) due presence variety biomolecules within them, such proteins RNAs, etc. play key role early detection, diagnosis, treatment, prognostic monitoring HCC. These influence development HCC therapeutic response ways, including influencing tumor microenvironment, resistance, participating immune regulatory mechanisms. In addition, specific molecules miRNAs are regarded markers for treatment recurrence which certain space prospects. this paper, we summarize aspects markers, also discuss questions that may be faced markers.

Language: Английский

Citations

0